Cupid Share Price Hits ₹368 as FY27 Profit Outlook Rises

Cupid shares rose more than 3% on Friday, October 9, to touch a record high of ₹368 on the BSE. The stock has gained 39% across seven of the past eight trading sessions, extending a rally supported by the company's improved business outlook and higher revenue and profit guidance for FY27.

Cupid has delivered a 15,400% return over five years and has gained about 230% in 2026 so far. The company's September quarter business update pointed to revenue of more than ₹200 crore for Q2FY27, while management raised its full year revenue target to ₹800 crore and net profit guidance to more than ₹250 crore.

The rally has also drawn attention to the stock's valuation and technical indicators. Market analysts have highlighted continued buying interest but warned that the sharp rise could lead to short term profit booking.

Cupid share price performance

Cupid shares have gained across multiple time periods, with the pace of the recent rally accelerating over the past six months. The stock has risen 292% in six months and 73% in three months, reflecting sustained buying interest. Its five year return stands at around 15,400%, making it a multibagger stock over the period.

The following table summarises the reported price performance.

Period	Share price gain
Five years	15,400%
2026 so far	About 230%
One year	656%
Six months	292%
Three months	73%
One month	30%
One week	16%
Seven of the past eight sessions	39%

The figures cover different periods and should not be added together. The gains also reflect past price movements and do not establish how the stock will perform in the future.

Cupid raises FY27 revenue and profit guidance

Cupid has raised its full year FY27 guidance after reporting stronger business momentum and improved visibility across domestic and international markets. The company expects total revenue for the September quarter to exceed ₹200 crore, as disclosed in an exchange filing dated September 30, 2026.

Management has increased its FY27 revenue guidance to ₹800 crore from the earlier range of ₹725 crore to ₹750 crore. Its net profit guidance has risen to more than ₹250 crore, compared with the previous range of ₹210 crore to ₹225 crore. The company attributed the revision to growth across its business segments, stronger prospects in domestic markets and international healthcare demand.

Financial metric	Earlier guidance	Revised guidance
FY27 revenue	₹725 crore to ₹750 crore	₹800 crore
FY27 net profit	₹210 crore to ₹225 crore	More than ₹250 crore
Q2FY27 revenue	Not specified	More than ₹200 crore

The September quarter revenue figure is an expectation disclosed by the company, not a confirmed final result in the supplied information. The actual quarterly performance will show how closely the business has tracked its outlook.

Cupid had previously cited a strong order book, continued demand in its international business to business healthcare operations and expansion of its consumer healthcare and FMCG portfolio as reasons for its earlier guidance.

What is driving Cupid's business outlook?

Cupid has identified several areas that it expects to support growth through the second half of FY27. The company expects momentum to continue in the third and fourth quarters, with improved visibility across institutional customers and private markets.

Its domestic FMCG business is another area of focus. Cupid plans to expand distribution through modern trade outlets, general trade retailers and pharmacy channels. Wider distribution could help the company reach more consumers, although the eventual effect on revenue and profit will depend on execution and demand.

The company is also working towards operationalising its Palava manufacturing facility. The facility is expected to improve production capacity, flexibility and supply capabilities for both domestic and overseas markets.

Cupid's healthcare and personal care portfolio is expected to remain part of its growth plans. Management has linked its revised guidance to the combined contribution of these businesses and its international healthcare operations.

Cupid's South Africa expansion and healthcare investment

Cupid has received in principle approval for a proposed manufacturing venture in South Africa. The project is intended to support local production and give the company a base from which to expand across African and other international markets.

The proposed venture is expected to follow an asset light model. Cupid plans to combine its manufacturing expertise with support from local partners to serve institutional procurement requirements and widen market access. The supplied information does not specify the project's investment amount, production capacity or expected commissioning date.

Separately, Cupid strengthened its healthcare partnership with GII Healthcare Investment Limited through an additional follow on investment of $5 million. The company has also continued to expand its domestic consumer business, with distribution and manufacturing capacity forming part of its growth plans.

These developments could support the company's attempt to increase its presence in international healthcare markets. Their contribution to the revised financial guidance will become clearer as the projects progress and the company reports subsequent results.

Cupid approves warrant conversion

During the September quarter, Cupid approved the conversion of up to 30 lakh warrants held by Baazar Style Retail Limited into an equivalent number of equity shares. The conversion price was set at ₹328.25 per share.

Particulars	Details
Warrant holder	Baazar Style Retail Limited
Warrants approved for conversion	Up to 30 lakh
Equivalent equity shares	Up to 30 lakh
Conversion price	₹328.25 per share

The approval allows the specified warrants to be converted into equity shares, subject to the applicable conversion process. The supplied information does not establish that all the warrants have already been converted.

Market analysis: what the rally indicates

Cupid's share price has moved sharply higher alongside the company's improved financial outlook. The revised guidance gives investors a fresh set of revenue and profit expectations to assess against upcoming results. However, the share price has also risen much faster than the underlying financial figures available in the supplied information, making the next earnings update important for evaluating whether operating performance is keeping pace with market expectations.

The company operates across personal care and international healthcare markets. It has also identified the global condom market as a potential source of industry demand, with expected compound annual growth of about 8.7% between FY23 and FY30. This is a market estimate cited in the supplied material, not a guarantee of Cupid's own growth rate.

For broader sector context, readers can also follow developments in pharma stocks and healthcare shares. Wider market conditions may affect investor appetite for individual stocks, including companies reporting strong growth expectations.

What analysts say about Cupid shares

Jigar S Patel, Senior Manager for Technical Research at Anand Rathi Share and Stock Brokers Limited, said Cupid remained in a strong uptrend but had become stretched after its recent rise. He identified ₹345 as an important support level and said a close below that level could indicate weakening momentum.

Patel's technical view was that the broader uptrend could remain intact while the stock held above the support zone on a closing basis. He also cautioned that the sharp move had increased the possibility of intermittent profit booking or a short term pullback.

Mayank Jain, market analyst at Share.Market by PhonePe, also pointed to strong buying interest after the stock moved above earlier resistance levels. He cited the following simple moving averages on the daily chart:

Technical indicator	Level
20 day simple moving average	₹293.07
50 day simple moving average	₹280.67
200 day simple moving average	₹160.38

Jain noted that the share price was trading well above these averages. He identified the 20 day moving average as an immediate support reference, followed by the 50 day moving average. These are technical observations, not guarantees of future price direction.

For readers tracking other listed companies, WeloMoney's coverage of Tata Motors' acquisition activity provides another example of how corporate developments can influence stock specific interest.

What investors should watch

Cupid's next updates will help determine whether its improved outlook translates into reported financial performance. The main developments to monitor include:

• Q2FY27 revenue against the company's expectation of more than ₹200 crore.
• Progress towards the revised FY27 revenue target of ₹800 crore and net profit guidance above ₹250 crore.
• The operational timeline for the Palava manufacturing facility.
• Progress on the proposed South African manufacturing venture and the partnership with GII Healthcare Investment Limited.
• Whether the share price sustains its technical support levels after the recent rally.

The ₹345 support identified by Patel and the moving average levels cited by Jain are different technical reference points. They should not be treated as company guidance or guaranteed price floors. The stock's future direction will depend on market conditions, trading activity and how its business performance compares with expectations.

About Cupid

Cupid is a Nashik based personal care company with an international healthcare business. Its operations include condom products and a broader healthcare and personal care portfolio. The company is seeking to expand its domestic FMCG distribution and international business to business healthcare operations while increasing its manufacturing capacity.

Frequently asked questions

Why is Cupid's share price rising?

Cupid shares have risen amid stronger business momentum and an upward revision to FY27 revenue and profit guidance. The stock touched a record high of ₹368 on October 9, 2026, and the company expects Q2FY27 revenue to exceed ₹200 crore.

What is Cupid's revised FY27 revenue guidance?

Cupid has raised its FY27 revenue guidance to ₹800 crore from the earlier range of ₹725 crore to ₹750 crore. The company cited continued business momentum and better visibility across domestic and international markets.

What is Cupid's revised FY27 profit guidance?

Cupid expects FY27 net profit to exceed ₹250 crore, up from its earlier guidance range of ₹210 crore to ₹225 crore. This is management guidance and should not be confused with a confirmed full year result.

What is the support level for Cupid shares?

Anand Rathi technical analyst Jigar S Patel identified ₹345 as an important support level for Cupid shares. Share.Market analyst Mayank Jain separately identified the 20 day simple moving average at ₹293.07 and the 50 day average at ₹280.67 as technical reference levels.

What is Cupid planning in South Africa?

Cupid has received in principle approval for a proposed manufacturing venture in South Africa. The company intends to use an asset light model with local partners to support local production and expand access to African and other international markets.

How much have Cupid shares gained over five years?

Cupid shares have gained around 15,400% over five years, according to the supplied figures. The stock has also risen about 230% in 2026 so far and 656% over the past year, although past returns do not predict future performance.